212 related articles for article (PubMed ID: 14686699)
41. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
Akhtar S; Maghfoor I
J Clin Oncol; 2005 Sep; 23(25):6261; author reply 6262. PubMed ID: 16135496
[No Abstract] [Full Text] [Related]
42. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy].
Korolenko VO; Gershanovich ML; Tikhonova VV
Vopr Onkol; 2004; 50(4):421-5. PubMed ID: 15605764
[No Abstract] [Full Text] [Related]
43. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
[TBL] [Abstract][Full Text] [Related]
44. Progress in immunotherapy rituximab.
El-Habbash MM; Alwindi AM
Saudi Med J; 2007 Nov; 28(11):1635-44. PubMed ID: 17965780
[TBL] [Abstract][Full Text] [Related]
45. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma.
Rothe A; Schulz H; Elter T; Engert A; Reiser M
Haematologica; 2004 Jul; 89(7):875-6. PubMed ID: 15257947
[TBL] [Abstract][Full Text] [Related]
46. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
[TBL] [Abstract][Full Text] [Related]
47. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
LaCasce AS; Freedman AS
Semin Hematol; 2008 Apr; 45(2):85-9. PubMed ID: 18381102
[TBL] [Abstract][Full Text] [Related]
48. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Ujjani C; Cheson BD
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
[TBL] [Abstract][Full Text] [Related]
49. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.
Maloney DG; Press OW
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 8):63-76. PubMed ID: 9830635
[TBL] [Abstract][Full Text] [Related]
50. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
Svoboda J; Kotloff R; Tsai DE
Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
[TBL] [Abstract][Full Text] [Related]
51. Clinical status and optimal use of rituximab for B-cell lymphomas.
McLaughlin P; White CA; Grillo-López AJ; Maloney DG
Oncology (Williston Park); 1998 Dec; 12(12):1763-9; discussion 1769-70, 1775-7,. PubMed ID: 9874849
[TBL] [Abstract][Full Text] [Related]
52. Should rituximab be used prior to autologous stem-cell transplantation for non-Hodgkin's lymphoma?
Rodriguez J
Nat Clin Pract Oncol; 2005 Feb; 2(2):74-5. PubMed ID: 16264876
[No Abstract] [Full Text] [Related]
53. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
54. Rituximab faster infusion for patients with non-Hodgkin's lymphoma in the United States: implications for nursing practice.
Dawson K
J Infus Nurs; 2013; 36(3):172-8. PubMed ID: 23558916
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
56. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
Vega MI; Huerta-Yepaz S; Garban H; Jazirehi A; Emmanouilides C; Bonavida B
Oncogene; 2004 Apr; 23(20):3530-40. PubMed ID: 15077178
[TBL] [Abstract][Full Text] [Related]
57. ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.
Williams ME
Curr Hematol Rep; 2004 Nov; 3(6):395-6. PubMed ID: 15496271
[No Abstract] [Full Text] [Related]
58. Clinical trials referral resource. Current clinical trials of the anti-CD20 monoclonal antibody rituximab.
Davis T; Gore-Langton RE; Cheson BD
Oncology (Williston Park); 2000 Oct; 14(10):1437, 1440-3. PubMed ID: 11098509
[No Abstract] [Full Text] [Related]
59. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
[TBL] [Abstract][Full Text] [Related]
60. Galiximab: a review.
Bhat S; Czuczman MS
Expert Opin Biol Ther; 2010 Mar; 10(3):451-8. PubMed ID: 20092425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
